for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Roche Holding AG

ROG.S

現在値

318.45CHF

変化

1.70(+0.54%)

出来高

1,471,793

本日のレンジ

315.80

 - 

319.35

52週レンジ

265.75

 - 

357.85

∙ 約20分前の相場を表示しています。

適時開示

FDA Grants Priority Review To Genentech’s Esbriet For Unclassifiable Interstitial Lung Disease

Jan 21 (Reuters) - Roche Holding AG <ROG.S>::FDA GRANTS PRIORITY REVIEW TO GENENTECH’S ESBRIET (PIRFENIDONE) FOR UNCLASSIFIABLE INTERSTITIAL LUNG DISEASE.FDA IS EXPECTED TO MAKE A DECISION ON APPROVAL BY MAY 2021.

Roche Says U.S. Will Purchase Additional Doses Of Regeneron’s Casirivimab, Imdevimab

Jan 12 (Reuters) - Roche Holding Ag <ROG.S>::ROCHE CONFIRMS US GOVERNMENT AGREEMENT TO PURCHASE ADDITIONAL DOSES OF REGENERON’S CASIRIVIMAB AND IMDEVIMAB.NEW AGREEMENT WITH U.S. COVERS 1.25 MILLION ADDITIONAL DOSES OF ANTIBODY COCKTAIL.CO AND REGENERON ARE COLLABORATING ON DEVELOPING AND MANUFACTURING CASIRIVIMAB AND IMDEVIMAB.REGENERON IS DISTRIBUTING ANTIBODY COCKTAIL IN US AND ROCHE WILL BE RESPONSIBLE FOR DISTRIBUTION OUTSIDE US.REGENERON IS RESPONSIBLE FOR DEVELOPMENT AND DISTRIBUTION OF TREATMENT IN US.ROCHE IS COLLABORATING WITH REGENERON, WITH AIM OF HAVING MORE THAN 2 MILLION TREATMENT DOSES AVAILABLE ANNUALLY.ROCHE IS PRIMARILY RESPONSIBLE FOR DEVELOPMENT AND DISTRIBUTION OF TREATMENT OUTSIDE U.S..ACTIVELY WORKING WITH GOVERNMENTS OUTSIDE OF US ON POTENTIAL SUPPLY AGREEMENTS.UNDER NEW AGREEMENT, US GOVERNMENT WILL PURCHASE UP TO 1.25 MILLION FINISHED DOSES OF CASIRIVIMAB AND IMDEVIMAB BY 30 JUNE 2021.

European Commission Approves Roche’s Phesgo For Patients With Her2-Positive Breast Cancer

Dec 23 (Reuters) - Roche Holding AG <ROG.S>::EUROPEAN COMMISSION APPROVES ROCHE’S PHESGO (FIXED-DOSE COMBINATION OF PERJETA AND HERCEPTIN FOR SUBCUTANEOUS INJECTION) FOR PEOPLE WITH HER2-POSITIVE BREAST CANCER.SUBCUTANEOUS ADMINISTRATION IS PREFERRED BY PATIENTS, PHYSICIANS AND HEALTHCARE PROVIDERS, AND IS ASSOCIATED WITH A REDUCTION IN HEALTHCARE COSTS.TREATMENT WITH PHESGO IS OVER 90% FASTER, ADMINISTERED UNDER SKIN IN JUST MINUTES COMPARED TO HOURS WITH INTRAVENOUS (IV) INFUSION OF PERJETA PLUS HERCEPTIN.APPROVAL IS BASED ON RESULTS FROM PIVOTAL PHASE III FEDERICA TRIAL, WHICH SHOWED THAT PHESGO DELIVERED NON-INFERIOR LEVELS OF PERJETA AND HERCEPTIN IN BLOOD AND COMPARABLE EFFICACY AND SAFETY VERSUS IV FORMULATIONS.

Health Canada Approves Venclexta In Combination With Azacitidine Or Low Dose Cytarabine For Untreated Acute Myeloid Leukemia

Dec 15 (Reuters) - Abbvie Inc <ABBV.N>::HEALTH CANADA APPROVES VENCLEXTA® (VENETOCLAX) IN COMBINATION WITH AZACITIDINE OR LOW DOSE CYTARABINE FOR UNTREATED ACUTE MYELOID LEUKEMIA (AML).HEALTH CANADA APPROVES VENCLEXTA (VENETOCLAX) IN COMBINATION WITH AZACITIDINE OR LOW DOSE CYTARABINE FOR UNTREATED ACUTE MYELOID LEUKEMIA (AML).

Roche Launches Mutation Test For Breast Cancer Patients

Dec 15 (Reuters) - Roche Holding AG <ROG.S>::ROCHE LAUNCHES COBAS PIK3CA MUTATION TEST FOR PATIENTS WITH ADVANCED OR METASTATIC BREAST CANCER IN COUNTRIES ACCEPTING THE CE MARK.GENETIC TEST IDENTIFIES MUTATIONS IN PIK3CA GENE THAT CAN CAUSE CELLS TO GROW UNCONTROLLABLY, WHICH MAY LEAD TO CANCER.LAUNCH OF COBAS PIK3CA MUTATION TEST FOR PATIENTS WITH ADVANCED OR METASTATIC BREAST CANCER.

FDA Approves Roche's OCREVUS Shorter 2-Hour Infusion For Relapsing And Primary Progressive Multiple Sclerosis

Dec 14 (Reuters) - Roche Holding AG <ROG.S>::FDA APPROVES ROCHE’S OCREVUS® (OCRELIZUMAB) SHORTER 2-HOUR INFUSION FOR RELAPSING AND PRIMARY PROGRESSIVE MULTIPLE SCLEROSIS.APPROVAL WAS BASED ON DATA FROM RANDOMISED, DOUBLE-BLIND ENSEMBLE PLUS STUDY.

Relay Therapeutics Announces Worldwide License Agreement And Collaboration With Genentech

Dec 14 (Reuters) - Relay Therapeutics Inc <RLAY.O>::RELAY THERAPEUTICS ANNOUNCES A WORLDWIDE LICENSE AND COLLABORATION AGREEMENT WITH GENENTECH FOR RLY-1971.RELAY THERAPEUTICS INC - WILL RECEIVE $75 MILLION UPFRONT AND IS ELIGIBLE TO RECEIVE AN ADDITIONAL $25 MILLION IN NEAR-TERM PAYMENTS.RELAY THERAPEUTICS INC - WILL RECEIVE $695 MILLION IN ADDITIONAL POTENTIAL MILESTONES, PLUS ROYALTIES ON GLOBAL NET PRODUCT SALES.RELAY THERAPEUTICS INC - GENENTECH WILL ASSUME DEVELOPMENT OF RLY-1971 WITH POTENTIAL TO EXPAND INTO MULTIPLE COMBINATION STUDIES.RELAY THERAPEUTICS INC - ALSO HAS RIGHT TO OPT IN TO A 50/50 U.S. PROFIT/COST SHARE ON RLY-1971.RELAY THERAPEUTICS INC - RETAINS RIGHT TO COMBINE RLY-1971 WITH ITS SELECTIVE FGFR2 AND MUTANT-SELECTIVE PI3KΑ PROGRAMS.RELAY THERAPEUTICS INC - WITH EXECUTION OF COLLABORATION, CO ANTICIPATES IT WILL HAVE CASH AND INVESTMENTS TO SUSTAIN OPERATIONS THROUGH 2024.

Roche Says Follow-Up Phase III Data Reinforce Long-Term Benefit Of Hemlibra

Dec 7 (Reuters) - Roche Holding AG <ROG.S>::NEW FOLLOW-UP PHASE III DATA REINFORCE LONG-TERM BENEFIT OF ROCHE'S HEMLIBRA FOR PEOPLE WITH HAEMOPHILIA A.WITH NEARLY THREE YEARS OF FOLLOW-UP, HEMLIBRA MAINTAINED LOW TREATED BLEED RATES AND WAS WELL TOLERATED IN PEOPLE WITH HAEMOPHILIA A OF ALL AGES, WITH AND WITHOUT FACTOR VIII INHIBITORS.PROPORTION OF PARTICIPANTS WHO EXPERIENCED ZERO TREATED BLEEDS INCREASED OVER COURSE OF STUDY PERIO.THESE DATA, PRESENTED AT ASH 2020, BUILD ON RESULTS PREVIOUSLY OBSERVED IN HAVEN STUDIES, ONE OF LARGEST PIVOTAL CLINICAL TRIAL PROGRAMMES IN HAEMOPHILIA A.

Roche Announces FDA Approval Of Xofluza For Prevention Of Influenza

Nov 24 (Reuters) - Roche Holding AG <ROG.S>::ROCHE ANNOUNCES FDA APPROVAL OF XOFLUZA FOR THE PREVENTION OF INFLUENZA FOLLOWING CONTACT WITH AN INFECTED PERSON.XOFLUZA IS FIRST SINGLE-DOSE INFLUENZA MEDICINE APPROVED TO PREVENT INFLUENZA FOR THOSE WHO HAVE HAD CONTACT WITH AN INFECTED PERSON (POST-EXPOSURE PROPHYLAXIS).ROCHE ALSO PROVIDES AN UPDATE ON SNDA FILING FOR XOFLUZA IN PAEDIATRIC SETTING.

Genentech Announces FDA Approval Of Xofluza For The Prevention Of Influenza Following Contact With An Infected Person

Nov 23 (Reuters) - Genentech::GENENTECH ANNOUNCES FDA APPROVAL OF XOFLUZA FOR THE PREVENTION OF INFLUENZA FOLLOWING CONTACT WITH AN INFECTED PERSON.DETERMINING PATH FORWARD WITH FDA FOR POTENTIAL INDICATION FOR XOFLUZA AS TREATMENT FOR ACUTE UNCOMPLICATED INFLUENZA IN PEDIATRIC SETTING.

金融情報はリフィニティブから。すべての情報は少なくとも20分遅れで表示されています。

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up